Cell and Gene Therapy 07/03/2018 Increasing Access to Cell and Gene Therapies: The Potential of... Could outcome-based annuity payments, in which cell and gene therapies are paid for over-time as benefits materialise, increase patient access to...
Cell and Gene Therapy 05/03/2018 The ROI of Automation in Cell-based Therapy Bioprocessing and... Phacilitate and Biolacuna have produced a cutting-edge report, which includes the results, data and analysis of an industry-wide survey, plus...
Cell and Gene Therapy 19/02/2018 Part Five: Commercialisation The supply chain story concludes with a focus on commercialisation and scale-up
Cell and Gene Therapy 19/02/2018 Part Four: Cryopreservation This report provides a comprehensive guide to successfully investing in advanced therapies. It also outlines across six chapters each of the...
Cell and Gene Therapy 19/02/2018 Part Three: Transportation This five-part supply chain case study series continues with one of the transportation
Cell and Gene Therapy 19/02/2018 Part Two: Registration and Workflow Management The second step in the supply chain case study series is registration and workflow management
Cell and Gene Therapy 19/02/2018 Part One: Supply Chain Planning This five-part supply chain case study series begins with one of the most important factors in the success of your supply chain. Planning
Cell and Gene Therapy 15/02/2018 Viral Safety for ATMPS - Part One Pathogen safety is a crucial but sometimes overlooked aspect of the development of advanced therapy medicinal products
Cell and Gene Therapy 15/02/2018 Infographic: Your Guide to Investing in Advanced Therapies In order to successfully invest in and realise the potential of advanced therapies, several technical factors must be well understood and...
Cell and Gene Therapy 08/02/2018 Video: How to Deliver Innovative Immunotherapies to Patients in the... The infrastructure of delivering immuno-oncology therapies is equal in importance to the science. the industry must develop clear plans for...
Immuno-oncology 08/02/2018 Video: Striking the Balance Between Regulatory Opportunities and... A video interview with Peter Olaganju, Senior Technical Director at Bluebird Bio. With every new opportunity comes great challenges
Cell and Gene Therapy 01/02/2018 Video: Advanced Therapies 2025 Industry leaders discuss the past, present and future of advanced therapies in this inspiring video...
Cell and Gene Therapy 31/01/2018 Winning Friends and Influencing Logistics in the Cell and Gene... Dr Alina Depkat is the customer relations manager at time:matters, a subsidiary of Lufthansa, the largest airline in Europe. She is leading...
Cell and Gene Therapy 31/01/2018 European Drug Makers Take the First Footsteps into the US Gene... NOVARTIS HAS MADE HISTORY AS THE FIRST PHARMA COMPANY TO GAIN APPROVAL OF A CAR-T PRODUCT BY THE FDA AND CAN BE CROWNED DEFINITIVE WINNERS OF WHAT...
Cell and Gene Therapy 31/01/2018 EMA Hooks Bluebird and Kite with Enticing Regulatory Pathways KITE PHARMA’S RECENT ANNOUNCEMENT OF A MARKETING AUTHORISATION APPLICATION TO THE EMA FOR THEIR LEAD PRODUCT, AXICABTAGENE CILOLEUCEL, HAS RE...
